Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin receptors as therapeutic drug targets
Anthony L. Gotter, Anthony J. Roecker, Richard Hargreaves, et al.
Progress in brain research (2012), pp. 163-188
Closed Access | Times Cited: 95

Showing 26-50 of 95 citing articles:

Orexin 2 receptor regulation of the hypothalamic–pituitary–adrenal (HPA) response to acute and repeated stress
Laura A. Grafe, Darrell Eacret, Sandra Luz, et al.
Neuroscience (2017) Vol. 348, pp. 313-323
Open Access | Times Cited: 50
Genetic associations between orexin genes and phenotypes related to behavioral regulation in humans, including substance use
Fazil Alıev, David De Sa Nogueira, Gary Aston‐Jones, et al.
Molecular Psychiatry (2025)
Open Access
Evaluation of leptin, insulin, orexin, neuropeptide y (NPY) levels in postmortem CSF samples in suicide deaths
Mehmet Tokdemir, Esra Erbak, Ferhat Turgut Tunçez, et al.
Journal of Affective Disorders (2025)
Closed Access
Electroencephalographic Power Spectral Density Profile of the Orexin Receptor Antagonist Suvorexant in Patients with Primary Insomnia and Healthy Subjects
Junshui Ma, Vladimir Svetnik, Ellen Snyder, et al.
SLEEP (2014) Vol. 37, Iss. 10, pp. 1609-1619
Open Access | Times Cited: 47
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
W. Joseph Herring, Thomas Roth, Andrew D. Krystal, et al.
Journal of Sleep Research (2018) Vol. 28, Iss. 2
Closed Access | Times Cited: 44
A Supervised Molecular Dynamics Approach to Unbiased Ligand–Protein Unbinding
Giuseppe Deganutti, Stefano Moro, Christopher A. Reynolds
Journal of Chemical Information and Modeling (2020) Vol. 60, Iss. 3, pp. 1804-1817
Open Access | Times Cited: 37
Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate
Michael A. Letavic, Pascal Bonaventure, Nicholas I. Carruthers, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 14, pp. 5620-5636
Closed Access | Times Cited: 38
Suvorexant for the Treatment of Insomnia in Adolescents
Kentaro Kawabe, Fumie Horiuchi, Marina Ochi, et al.
Journal of Child and Adolescent Psychopharmacology (2017) Vol. 27, Iss. 9, pp. 792-795
Closed Access | Times Cited: 37
Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement
Jason M. Uslaner, Christopher J. Winrow, Anthony L. Gotter, et al.
Behavioural Brain Research (2014) Vol. 269, pp. 61-65
Closed Access | Times Cited: 35
Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior
Natalie E. Zlebnik, Nathan A. Holtz, Victoria C. Lepak, et al.
Drug and Alcohol Dependence (2021) Vol. 224, pp. 108719-108719
Open Access | Times Cited: 24
Kinetic properties of “dual” orexin receptor antagonists at OX1R and OX2R orexin receptors
Gabrielle E. Callander, Morenike Olorunda, Dominique Monna, et al.
Frontiers in Neuroscience (2013) Vol. 7
Open Access | Times Cited: 35
The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship
Andrezza K. Kim, Robyn M. Brown, Andrew J. Lawrence
Frontiers in Behavioral Neuroscience (2012) Vol. 6
Open Access | Times Cited: 33
Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction
Coleman B. Calva, Jim R. Fadel
Brain Research (2018) Vol. 1731, pp. 145921-145921
Open Access | Times Cited: 28
Discovery of MK-3697: A selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia
Anthony J. Roecker, Thomas S. Reger, M. Christa Mattern, et al.
Bioorganic & Medicinal Chemistry Letters (2014) Vol. 24, Iss. 20, pp. 4884-4890
Closed Access | Times Cited: 28
Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts
Vladimir Svetnik, Ellen Snyder, Peining Tao, et al.
SLEEP (2017) Vol. 41, Iss. 1
Open Access | Times Cited: 28
Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects
Arie Struyk, Cynthia Gargano, Melissa Drexel, et al.
European Neuropsychopharmacology (2016) Vol. 26, Iss. 10, pp. 1649-1656
Closed Access | Times Cited: 25
Targeting the Orexin System for Prescription Opioid Use Disorder
Alessandra Matzeu, Rémi Martin‐Fardon
Brain Sciences (2020) Vol. 10, Iss. 4, pp. 226-226
Open Access | Times Cited: 22
Corticotropin releasing hormone and imaging, rethinking the stress axis
Carlo Contoreggi
Nuclear Medicine and Biology (2014) Vol. 42, Iss. 4, pp. 323-339
Open Access | Times Cited: 24
Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity
Ainoleena Turku, Maiju K. Rinne, Gustav Boije af Gennäs, et al.
PLoS ONE (2017) Vol. 12, Iss. 6, pp. e0178526-e0178526
Open Access | Times Cited: 22
Azulene-based compounds for targeting orexin receptors
Teppo O. Leino, Ainoleena Turku, Jari Yli‐Kauhaluoma, et al.
European Journal of Medicinal Chemistry (2018) Vol. 157, pp. 88-100
Closed Access | Times Cited: 21
Why Does Sleep Stop Migraine?
Marcelo E. Bigal, Richard Hargreaves
Current Pain and Headache Reports (2013) Vol. 17, Iss. 10
Closed Access | Times Cited: 22
Truncated Orexin Peptides: Structure–Activity Relationship Studies
Nadezhda German, Ann M. Decker, Brian P. Gilmour, et al.
ACS Medicinal Chemistry Letters (2013) Vol. 4, Iss. 12, pp. 1224-1227
Open Access | Times Cited: 21
Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin‐A (hypocretin‐1)
Coleman B. Calva, Habiba Fayyaz, Jim R. Fadel
Journal of Neurochemistry (2017) Vol. 145, Iss. 3, pp. 232-244
Open Access | Times Cited: 21
Synthesis of [11C]MK-1064 as a new PET radioligand for imaging of orexin-2 receptor
Mingzhang Gao, Min Wang, Qi-Huang Zheng
Bioorganic & Medicinal Chemistry Letters (2016) Vol. 26, Iss. 15, pp. 3694-3699
Open Access | Times Cited: 19
Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands
Ainoleena Turku, Alexandre Borrel, Teppo O. Leino, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 18, pp. 8263-8275
Closed Access | Times Cited: 19

Scroll to top